Answers are grounded in this paper and cite their sources.
JX-594 is a modified oncolytic poxvirus designed to selectively replicate in and destroy cancer cells. In a pilot study, JX-594 injection followed by sorafenib was well-tolerated in three patients and associated with objective tumor responses. In this study, we report a case in which a patient with advanced hepatocellular carcinoma and portal vein thrombosis was treated with a combination of JX-594 and sorafenib.
No takes yet. Share an insight, caveat, or question.
Jo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: